Compass Pathways Finalized Psilocybin Submission

The company has prepared its rolling FDA submission for a synthetic psilocybin treatment designed for depression.

Updated on Oct. 15, 2026 in Mental Health

Compass Pathways Finalized Psilocybin Submission

Live Poll

Should new psychedelic therapies be rolled out slowly to ensure safety despite the need for access?

Compass Pathways is finalizing a rolling FDA submission for COMP360, a synthetic psilocybin treatment aimed at addressing treatment-resistant depression. The firm plans to launch the therapy early next year, pending regulatory approval.

Why it matters

Compass Pathways is training providers and negotiating with insurers to ensure positive initial experiences and prevent setbacks that could harm the broader field. This strategic approach follows the FDA's rejection of an MDMA-based therapy from Lykos Therapeutics in 2024.

In Phase 3 trials, 25% of patients showed a response after one dose, while 40% responded after a second dose three weeks later. Treatment involves a six-hour supervised session, with benefits potentially lasting up to one year.

The players

Compass Pathways

This mental health company focuses on developing evidence-based psychedelic therapies to treat complex psychiatric disorders.

Lykos Therapeutics

This biopharmaceutical organization is known for its research into MDMA-assisted therapy for post-traumatic stress disorder.

The details

The treatment involves a six-hour supervised session, during which participants spend approximately 80% of the time in silence. Compass Pathways is currently working with the Centers for Medicare and Medicaid Services to secure reimbursement models for this monitoring.

In 2024, the FDA rejected an MDMA-based therapy proposed by Lykos Therapeutics.
Compass Pathways is completing its rolling FDA submission in Q4 2026.
A potential launch for the COMP360 treatment is planned for early 2027.

Health Landscape

This development follows the 2024 FDA rejection of MDMA-based therapy, highlighting the intense regulatory scrutiny facing psychedelic-assisted treatments. Companies are increasingly focused on refining provider training to prove the long-term viability of these therapies within the mainstream healthcare system.

Patients dealing with treatment-resistant depression may gain access to a new therapy option by early 2027, provided it receives FDA approval. The treatment will likely require adherence to a specific risk evaluation and mitigation strategy to ensure patient safety.

The takeaway

The success of new mental health treatments often depends as much on the regulatory and insurance infrastructure as it does on clinical efficacy. Patients and providers should monitor official FDA updates regarding the mandatory risk management protocols for this new therapy.